A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
- Conditions
- Infusion Reaction
- Registration Number
- NCT01156090
- Lead Sponsor
- SCRI Development Innovations, LLC
- Brief Summary
The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 141
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of Vectibix-related infusion reactions w/high rate of Erbitux-related infusion reactions February 2004 -April 2009 To determine the rate of Vectibix (Panitumumab)-related infusion reactions (CTCAE v3.0 grade I-IV) in geographic areas of the United States associated with a high rate of Erbitux-related infusion reactions
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
St. Louis Cancer Care
🇺🇸Chesterfield, Missouri, United States
South Carolina Oncology Associates, PA
🇺🇸Columbia, South Carolina, United States
Northeast Georgia Medical Center
🇺🇸Gainesville, Georgia, United States
Medical Oncology Associates of Augusta
🇺🇸Augusta, Georgia, United States
Baptist Hospital East
🇺🇸Louisville, Kentucky, United States
Tennessee Oncology, PLLC
🇺🇸Nashville, Tennessee, United States
Northeast Arkansas Clinic
🇺🇸Jonesboro, Arkansas, United States